People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor ...

Eli Lilly plans to invest at least $27 billion ... including engineers, scientists, operations personnel and lab technicians," along with nearly 10,000 construction jobs. Site locations are ...

Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...

The fourth location would extend Eli Lilly's global parenteral manufacturing network for future injectable therapies. The four sites would create more than 3,000 jobs for scientists, engineers ...

Dan Skovronsky knows what makes a good obesity drug. As chief scientific officer at Eli Lilly, he's already done it once with the company's weekly shot, Zepbound. He's trying to do it again with a ...

The University of Copenhagen is excited to announce Maxwell Biosciences as Tier 1 Sponsor of the 12th Aging Research & Drug ...

Eli Lilly and Co. Wednesday announced plans to ... Lilly expects to create 3,000 highly skilled manufacturing jobs for engineers, scientists, operations personnel and lab technicians along with ...